IMAB

$0.00

(

0.00%

)
Quote details

stock

I-Mab

NASDAQ | IMAB

4.63

USD

(

0.00%

)

At Close (As of Jan 1, 1970)

$533.68M

Market Cap

-

P/E Ratio

-0.51

EPS

$6.79

52 Week High

$0.59

52 Week Low

HEALTHCARE

Sector

IMAB Chart

Recent Chart
Price Action

IMAB Technicals

Tags:

IMAB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$375M
Selling General And Administrative $216M
Research And Development $159M
Operating Expenses $375M
Investment Income Net -
Net Interest Income $7.5M
Interest Income $7.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.9M
Income Before Tax -$363M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$50M
Comprehensive Income Net Of Tax -
Ebit -$375M
Ebitda -$373M
Net Income -$162M

Revenue & Profitability

Earnings Performance

IMAB Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $213M
Total Current Assets $177M
Cash And Cash Equivalents At Carrying Value $68M
Cash And Short Term Investments $68M
Inventory -
Current Net Receivables $1.2M
Total Non Current Assets $36M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $31M
Short Term Investments $105M
Other Current Assets $2.1M
Other Non Current Assets -
Total Liabilities $12M
Total Current Liabilities $8.5M
Current Accounts Payable -
Deferred Revenue -
Current Debt -
Short Term Debt $816K
Total Non Current Liabilities $3.1M
Capital Lease Obligations $3.9M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.9M
Other Current Liabilities $7.5M
Other Non Current Liabilities -
Total Shareholder Equity $201M
Treasury Stock -
Retained Earnings -$1.3B
Common Stock $19K
Common Stock Shares Outstanding $81M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$53M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $978K
Capital Expenditures $48K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$136M
Cashflow From Financing -$335K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$335K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$50M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$375M
Selling General And Administrative $216M
Research And Development $159M
Operating Expenses $375M
Investment Income Net -
Net Interest Income $7.5M
Interest Income $7.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.9M
Income Before Tax -$363M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$50M
Comprehensive Income Net Of Tax -
Ebit -$375M
Ebitda -$373M
Net Income -$162M

IMAB Profile

I-Mab Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

I-Mab is a leading clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative biologics for cancer and autoimmune disorders. With a robust pipeline and strong research capabilities, I-Mab is dedicated to addressing significant unmet medical needs in both domestic and international markets. The company's strategic focus on cutting-edge therapies positions it as a key player in the biopharmaceutical sector, with the potential to drive meaningful advancements in healthcare and improve patient outcomes.

VHAI
+100.00%
$0.00
LPTX
+368.57%
$2.05
IVP
-2.25%
$0.12
NVDA
+2.05%
$182.55
ENLV
+13.73%
$1.02
TWOH
-34.78%
$0.00
ONDS
+7.41%
$6.73
PLUG
-1.01%
$1.96
INTC
+3.73%
$35.79
AEHL
+109.09%
$2.53
TSLA
+6.82%
$417.78
VSA
+3.29%
$0.18
GRAB
+7.14%
$5.25
BYND
+0.96%
$0.87
DVLT
-5.09%
$2.42
BITF
-6.53%
$2.43
GOOGL
+3.52%
$299.66
NVO
-5.54%
$44.99
PLTR
-0.57%
$154.85
BMNR
+19.76%
$31.14
ASST
+12.74%
$1.15
KTTA
+45.33%
$0.42
AXDX
-61.36%
$0.03
SGMO
+9.97%
$0.42
SOFI
+8.77%
$27.40
PFE
+0.77%
$25.23
T
+1.60%
$25.93
OSCR
+22.32%
$16.49
GELS
+20.38%
$1.06
MARA
-1.66%
$10.07
AMZN
+2.53%
$226.28
NWTN
-5.10%
$0.74
BAC
+0.65%
$51.90
NIO
+3.13%
$5.75
AAL
+1.78%
$13.10
ADAP
-15.14%
$0.05
IREN
-2.78%
$42.26
AVGO
+11.09%
$377.96
CJET
-33.15%
$1.27
BTBT
+9.56%
$2.29
DNN
+2.64%
$2.33
VZ
-2.46%
$40.21
GOOG
+3.33%
$299.65
CHR
-1.21%
$0.05
AMD
+5.53%
$215.05
GPUS
+21.57%
$0.25
SOND
-23.45%
$0.12
WMT
-1.17%
$104.08
PCG
+1.75%
$15.94
NFLX
-1.28%
$104.31
RIVN
+1.36%
$14.86
RMBL
+60.50%
$3.21
KO
-0.53%
$72.56
WBD
-1.33%
$22.86
LNW
-3.71%
$86.22
AAPL
+1.56%
$275.74
KVUE
+0.48%
$16.72
ADD
-25.47%
$0.05
CLSK
+17.98%
$11.48
BTG
+9.31%
$4.16
WULF
+11.86%
$12.63
F
+1.01%
$12.96
MU
+2.97%
$207.37
SNAP
-0.13%
$7.68
CIFR
+16.39%
$16.47
TLRY
+6.52%
$0.96
HPE
+2.75%
$21.08
BULL
+0.48%
$8.29
SRM
+53.27%
$10.30
RIG
+3.08%
$4.01
ACHR
+3.55%
$7.43
CGC
+9.90%
$1.11
MSFT
-1.31%
$472.12
PLTD
-4.69%
$7.31
ORCL
+0.81%
$200.37
AMCR
+1.67%
$8.50
NOK
+2.52%
$6.09
HOOD
+7.14%
$114.97
SLB
-1.27%
$35.73
CRWV
+2.72%
$73.60
QBTS
+13.13%
$23.09
IONQ
+1.73%
$41.71
DFLI
+4.90%
$0.78
OSRH
+15.48%
$0.64
JOBY
+0.23%
$13.07
WLGS
-5.57%
$0.04
RGTI
+9.92%
$25.93
ABEV
+2.01%
$2.53
VIVK
+10.52%
$0.14
MTSR
-0.35%
$70.50
ATON
-6.16%
$2.74
SMCI
+3.51%
$33.32
WFC
+1.72%
$84.54
FLEX
+3.00%
$56.95
BMNU
+39.92%
$7.36
APLD
+12.80%
$23.79
CAN
+5.55%
$0.96
AMZE
+21.51%
$0.30
NVTS
+0.13%
$7.56
AGNC
+2.08%
$10.28
VHAI
+100.00%
$0.00
LPTX
+368.57%
$2.05
IVP
-2.25%
$0.12
NVDA
+2.05%
$182.55
ENLV
+13.73%
$1.02
TWOH
-34.78%
$0.00
ONDS
+7.41%
$6.73
PLUG
-1.01%
$1.96
INTC
+3.73%
$35.79
AEHL
+109.09%
$2.53
TSLA
+6.82%
$417.78
VSA
+3.29%
$0.18
GRAB
+7.14%
$5.25
BYND
+0.96%
$0.87
DVLT
-5.09%
$2.42
BITF
-6.53%
$2.43
GOOGL
+3.52%
$299.66
NVO
-5.54%
$44.99
PLTR
-0.57%
$154.85
BMNR
+19.76%
$31.14
ASST
+12.74%
$1.15
KTTA
+45.33%
$0.42
AXDX
-61.36%
$0.03
SGMO
+9.97%
$0.42
SOFI
+8.77%
$27.40
PFE
+0.77%
$25.23
T
+1.60%
$25.93
OSCR
+22.32%
$16.49
GELS
+20.38%
$1.06
MARA
-1.66%
$10.07
AMZN
+2.53%
$226.28
NWTN
-5.10%
$0.74
BAC
+0.65%
$51.90
NIO
+3.13%
$5.75
AAL
+1.78%
$13.10
ADAP
-15.14%
$0.05
IREN
-2.78%
$42.26
AVGO
+11.09%
$377.96
CJET
-33.15%
$1.27
BTBT
+9.56%
$2.29
DNN
+2.64%
$2.33
VZ
-2.46%
$40.21
GOOG
+3.33%
$299.65
CHR
-1.21%
$0.05
AMD
+5.53%
$215.05
GPUS
+21.57%
$0.25
SOND
-23.45%
$0.12
WMT
-1.17%
$104.08
PCG
+1.75%
$15.94
NFLX
-1.28%
$104.31
RIVN
+1.36%
$14.86
RMBL
+60.50%
$3.21
KO
-0.53%
$72.56
WBD
-1.33%
$22.86
LNW
-3.71%
$86.22
AAPL
+1.56%
$275.74
KVUE
+0.48%
$16.72
ADD
-25.47%
$0.05
CLSK
+17.98%
$11.48
BTG
+9.31%
$4.16
WULF
+11.86%
$12.63
F
+1.01%
$12.96
MU
+2.97%
$207.37
SNAP
-0.13%
$7.68
CIFR
+16.39%
$16.47
TLRY
+6.52%
$0.96
HPE
+2.75%
$21.08
BULL
+0.48%
$8.29
SRM
+53.27%
$10.30
RIG
+3.08%
$4.01
ACHR
+3.55%
$7.43
CGC
+9.90%
$1.11
MSFT
-1.31%
$472.12
PLTD
-4.69%
$7.31
ORCL
+0.81%
$200.37
AMCR
+1.67%
$8.50
NOK
+2.52%
$6.09
HOOD
+7.14%
$114.97
SLB
-1.27%
$35.73
CRWV
+2.72%
$73.60
QBTS
+13.13%
$23.09
IONQ
+1.73%
$41.71
DFLI
+4.90%
$0.78
OSRH
+15.48%
$0.64
JOBY
+0.23%
$13.07
WLGS
-5.57%
$0.04
RGTI
+9.92%
$25.93
ABEV
+2.01%
$2.53
VIVK
+10.52%
$0.14
MTSR
-0.35%
$70.50
ATON
-6.16%
$2.74
SMCI
+3.51%
$33.32
WFC
+1.72%
$84.54
FLEX
+3.00%
$56.95
BMNU
+39.92%
$7.36
APLD
+12.80%
$23.79
CAN
+5.55%
$0.96
AMZE
+21.51%
$0.30
NVTS
+0.13%
$7.56
AGNC
+2.08%
$10.28

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.